Treatment Algorithms: Dyslipidemia – Statin monotherapies dominate the market but uncontrolled lipid levels remain an issue

  • OVERVIEW
    • Catalyst
    • Summary
  • EXECUTIVE SUMMARY
    • Datamonitor key findings
    • Related reports
  • TREATMENT ALGORITHMS AND PATIENT PROFILES
    • Methodology
    • Patient profiles: seven major markets
    • Treatment algorithm: seven major markets
  • DISEASE DEFINITION AND DIAGNOSIS
    • Disease definition
    • Etiology
      • Lifestyle is the most common cause of dyslipidemia
    • Prognosis
      • Dyslipidemia is generally asymptomatic, but it can lead to symptomatic cardiovascular disease
    • Presentation and diagnosis
      • As an asymptomatic disease, country-wide screening is recommended to limit cardiovascular risk
      • Over half of dyslipidemia patients are undiagnosed
    • Treatment rates
      • Lifestyle management effectiveness is limited by under-prescription and low compliance
      • Variations in treatment guidelines affect reported treatment rates
      • Reported compliance rates vary considerably across the seven major markets
  • PATIENT SEGMENTATION
    • Segmentation by lipid levels
    • Pure hypertriglyceridemia is less common than cholesterol-related dyslipidemias
    • High-density lipoprotein cholesterol
    • Familial hypercholesterolemia
  • CURRENT TREATMENT OPTIONS
    • Overview of the antidyslipidemic drug classes
    • Prescribing trends
      • Prescription trends for specific dyslipidemia subgroups are based on antidyslipidemic class efficacy
      • Class usage across the seven markets is largely consistent
    • Prescribing strategies
      • Therapy switching is most commonly due to insufficient lipid modulation
      • Generic antidyslipidemics continue to take market share from key brands following Lipitor's patent expiry
  • PRESCRIBING INFLUENCES AND UNMET NEEDS
    • Prescribing influences
      • (Untitled sub-section)
    • Treatment outcomes: unmet needs
      • Physicians’ highest priority unmet needs: antidyslipidemics with stronger efficacy at improving lipid deviations
  • BIBLIOGRAPHY
    • Journal papers
    • Websites
    • Datamonitor reports
  • APPENDIX
    • Physician data
    • Survey questionnaire
      • Screener
      • Introduction
      • Diagnosis and patient segmentation
      • 3.0 Treatment Regimens
      • 4. 0 Co-morbidities / compelling indications
      • 5 Compliance
      • 6.0 Clinical need in dyslipidemia
      • 7.0 Pipeline and recently launched drugs
      • 8.0 Prescribing influences
      • 9.0 Switching therapies
      • DEMOGRAPHICS
    • Report methodology
  • TABLES
    • Table: Common etiologies and risk factors of dyslipidemia and their effect on lipid levels
    • Table: An overview of the antidyslipidemic drug classes in the seven major markets, 2012
    • Table: Physicians’ clinical needs ranked according to importance, 2012
    • Table: The proportion of patients that have uncontrolled lipid levels across the seven major markets, by subtype, 2012
    • Table: Survey respondents across the seven major markets, by country, 2012
  • FIGURES
    • Figure: Dyslipidemia patient profiles across the seven major markets, 2012
    • Figure: Dyslipidemia treatment regimens for the seven major markets, by subgroup, 2012
    • Figure: Proportion of patients receiving antidyslipidemics with co-morbidities or compelling indications in the seven major markets, 2012
    • Figure: Proportion of patients with the most common compelling indications, diabetes and obesity, across the seven major markets, 2012
    • Figure: Diagnosed dyslipidemia patients as a proportion of the prevalent patient population in the seven major markets, 2012
    • Figure: Dyslipidemia patients treated with drug therapy as a proportion of the diagnosed patient population in the seven major markets, 2012
    • Figure: Compliance rates for pure hypercholesterolemia pharmacotherapy in the seven major markets, by country, 2012
    • Figure: Compliance rates for pure hypertriglyceridemia pharmacotherapy in the seven major markets, by country, 2012
    • Figure: Compliance rates for mixed hyperlipidemia pharmacotherapy in the seven major markets, by country, 2012
    • Figure: The proportion of diagnosed patients within each subgroup (pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia) across the seven major markets, 2012
    • Figure: Proportion of each dyslipidemic subgroup that have also been diagnosed with low HDL-C across the seven major markets, 2012
    • Figure: The proportion of diagnosed hypercholesterolemia patients that have familial hypercholesterolemia across the seven major markets, 2012
    • Figure: The proportion of patients in each subgroup prescribed antidyslipidemics across the seven major markets, by class, 2012
    • Figure: Antidyslipidemic drug class usage in each dyslipidemia subgroup (pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia) in the US, 2012
    • Figure: Antidyslipidemic drug class usage in each dyslipidemia subgroup (pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia) in Japan, 2012
    • Figure: Antidyslipidemic drug class usage in each dyslipidemia subgroup (pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia) in the five major EU markets, 2012
    • Figure: Proportion of patients receiving one or more antidyslipidemic drug, 2012
    • Figure: Physician reported patients who were prescribed either the generic of branded forms of atorvastatin in February, 2012
    • Figure: Proportion of patients currently receiving Lipitor and Crestor that are expected to switch or have switched to generic atorvastatin following Lipitor's loss of patent exclusivity, 2012
    • Figure: Physician-reported prescribing influences, ranked by importance, 2012
    • Figure: Factors influencing prescribing decisions when choosing between a fixed-dose combination and a free-dose combination, ranked according to their impact, 2012
    • Figure: Mean satisfaction scores given to antidyslipidemic treatments based on their ability to modify specific lipid levels, 2012

Report

Published by
Datamonitor
Published on
08 May 2012
Product code
HC00194-009
Pages
Please wait...

$7600

Multi-user License $19000